

Expert Review of Neurotherapeutics

PROPERTY OF THE
NATIONAL
LIBRARY OF
MEDICINE



Expert Reviews Ltd
01473-7173

EDITORIALS

Ironing out neurodegeneration: importance of iron intake during teenage years

Should the Social Cognition and Emotional Assessment replace standard neuropsychological tests for frontotemporal dementia?

The use of informant-based questionnaires in differentiating mild cognitive impairment from normal aging

DRUG PROFILE

Lacosamide for the treatment of partial-onset seizures

KEY PAPER EVALUATION

Associations of alcohol consumption with clinical and MRI measures in MS

SPECIAL REPORTS

The management of Parkinson's disease in sub-Saharan Africa

Recent and future antiepileptic drugs and their impact on cognition

REVIEWS

Evaluation of the Braak hypothesis: can it explain the pathogenesis of PD?

Distinguishing essential tremor from Parkinson's disease: bedside tests and laboratory evaluations

Autonomic dysfunction in Parkinson's disease

Second-generation antiepileptic drugs and pregnancy: a guide for clinicians

The impact of positron emission tomography imaging on the clinical management of patients with epilepsy

Angiogenic inhibition in high-grade gliomas: past, present and future

EXPERT
REVIEWS

Argentum Pharm. v. Research Corp. Techs., IPR2016-00204

RCT EX 2120 - 1/17

Expert Review of

Neurotherapeutics

June 2012

Expert Rev. Neurother. 12(6)

Editorials

629 Ironing out neurodegeneration: is iron intake important during the teenage years?

PM Thompson & N Jahanshad

633 Should the Social Cognition and Emotional Assessment replace standard neuropsychological tests for frontotemporal dementia?

M Sarazin, B Dubois, LC de Souza & M Bertoux

637 The use of informant-based questionnaires in differentiating mild cognitive impairment from normal aging

MN Sabbagh, M Malek-Ahmadi & CM Belden

641 News in brief

- Tau protein and amyloid combination key to Alzheimer's disease progression, research suggests
- Can progression of cognitive decline can be altered by exercise?
- Study suggests association of genes with post-traumatic stress disorder
- New MRI technique may help visualize spread of dementia
- Alternative classification system for autism allows more rapid diagnosis
- A possible dendrimer-based treatment for cerebral palsy

Drug Profile

645 Lacosamide for the treatment of partial-onset seizures

V Biton

Key Paper Evaluation

657 Associations of alcohol consumption with clinical and MRI measures in multiple sclerosis

MB D'hooghe & J De Keyser

Special Reports

661 The management of Parkinson's disease in sub-Saharan Africa

C Dotchin & R Walker

667 Recent and future antiepileptic drugs and their impact on cognition: what can we expect?

M Mula

Reviews

PARKINSON'S DISEASE

673 Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease?

G Halliday, H McCann & C Shepherd

687 Distinguishing essential tremor from Parkinson's disease: bedside tests and laboratory evaluations

MA Thenganatt & ED Louis

697 Autonomic dysfunction in Parkinson's disease

RF Pfeiffer

Contents continued overleaf...

EXPERT
REVIEWS

Continued

Reviews (cont.)

EPILEPSY

707 Second-generation antiepileptic drugs
and pregnancy: a guide for clinicians
A Reimers & E Brodtkorb

719 The impact of positron emission
tomography imaging on the clinical
management of patients with epilepsy
C Juhász

GENERAL

733 Angiogenic inhibition in high-grade
gliomas: past, present and future
J Jo, D Schiff & B Purow

Appendices

749 Acknowledgements

750 Author Guidelines
Calendar

EXPERT
REVIEWS

Expert Rev. Neurother. 12(6), (2012)

Argentum Pharm. v. Research Corp. Techs., IPR2016-00204

Neurotherapeutics

Chairman:
James Drake

Managing Director:
David Hughes

Publisher:
Elisa Manzotti

**COMMISSIONING
DIRECTOR:**
Diana Meyer

**Senior Manager
Integral Development:**
Lara Bonner

**Senior Manager
Commissioning:**
Victoria Lane

**Head of Commissioning
Trace O'Neill**

Draft Profiles Editor:
Rosanna Cusumano

**PRODUCTION
DEPARTMENT:**

**Senior Manager
Graphics & Production:**
Karen Rowland

Head of Production:
Zara Robinson

**Junior Managing
Production Editor:**
Kat Gould

Production Editor:
Kelly Strong

**Assistant
Production Editors:**
Robin Parker
Debrah Robinson
Georgia Parry

Editorial Board

Aminoff MJ , UCSF, CA, USA	Lee H-G , Case Western Reserve University, USA
Benbadis SR , University of South Florida, FL, USA	Lesniak MS , University of Chicago, IL, USA
Billir J , Loyola University Chicago, IL, USA	Lukasiewicz M , INSERM, Paris, France
Brodie MJ , University of Glasgow, Scotland, UK	Lutsep HL , Oregon Stroke Center, OR, USA
Chamberlain MC , Uni. of South Florida, Tampa, USA	Mahapatra AK , India Institute, New Delhi, India
Chesselet M-F , UCLA, CA, USA	Mastaglia FL , Uni. of Western Australia, Australia
Diener H-C , University of Essen, Germany	Nobile-Orazio E , Milan University, Italy
Drachman DA , Uni. of MA Med. School, MA, USA	Olanow W , Mt. Sinai School of Medicine, NY, USA
Dudek FE , Colorado State University, CO, USA	Perry G , University of Texas at San Antonio, USA
Gauthier S , McGill Ctr for Studies in Aging, Canada	Perucca E , University of Pavia, Italy
Giacobini E , Uni. Hospitals of Geneva, Switzerland	Poewe W , University of Innsbruck, Austria
Hardiman O , Beaumont Hospital, Ireland	Post RM , National Institute of Mental Health, USA
Hindmarch I , HPRU Medical Research Centre, UK	Rabinowitz T , University of Vermont, VT, USA
Jankovic J , Baylor College of Medicine, TX, USA	Schneider J , Thomas Jefferson University, PA, USA
Jiménez-Jiménez FJ , University of Alcalá, Spain	Stojanovic MP , Massachusetts Gen. Hospital, USA
Kira J , Kyushu University, Japan	Tanabe H , Ehime Uni. School of Medicine, Japan
Kozubski W , University of Medical Sciences, Poland	Taupin P , Dublin City University, Ireland
Krymchantowski AV , Headache Ctr Rio de Janeiro	Yuki N , Niigata National Hospital, Japan

Disclaimer: Whilst every effort is made by the Publisher and Editorial Board to ensure that no inaccurate or misleading data, opinions or statements appear in this journal, they wish to make it clear that the data and opinions appearing herein are the responsibility of the contributor concerned. Accordingly, the Publisher, Editorial Board and their respective employees, officers and agents accept no liability whatsoever for the consequences of any inaccurate or misleading data, opinions or statements.

Copyright: Conditions of sale: *Expert Review of Neurotherapeutics* may be circulated only to those members of staff who are employed at the site at which the subscription is taken out. Readers are reminded that, under internationally agreed copyright legislation, photocopying of copyright materials is prohibited other than on a limited basis for personal use. Thus making copies of any article published in *Expert Review of Neurotherapeutics* is a breach of the law and can be prosecuted.

Indexing: Medline/
Index Medicus, EMBASE/
Excerpta Medica, Chemical
Abstracts and Science
Citation Index Expanded

ISSUE THEMES:

January/July
Schizophrenia; Mood disorders

February/August
Stroke; Anxiety disorders

March/September
Migraine and headache; Demyelinating
diseases

April/October
Nervous system neoplasms; ADHD

May/November
Alzheimer's disease; Pain

June/December
Parkinson's disease; Epilepsy

ENQUIRIES

Advertising	Sarah Bishop, Business Development Executive s.bishop@expert-reviews.com
Editorial	Elisa Manzotti, Publisher e.manzotti@expert-reviews.com
Subscriptions	sales@expert-reviews.com
Reprint	Sam Cavana, Reprint Sales Manager s.cavana@expert-reviews.com
Permissions	Javonne Molloy, Permissions Coordinator j.molloy@expert-reviews.com
Online	Online Access Team m.connolly@expert-reviews.com

www.expert-reviews.com



part of the

Argentum Pharm. v. Research Corp. Techs., IPR2016-00204
RCT EX. 2120 - 4/17

“...highly authoritative coverage of the rapidly changing neurological landscape...”

Expert Review of Neurotherapeutics provides expert reviews on the use of drugs and medicines in clinical neurology and neuropsychiatry. Coverage includes disease management, new medicines and drugs in neurology, therapeutic indications, diagnostics, medical treatment guidelines and neurological diseases such as stroke, epilepsy, Alzheimer's and Parkinson's.

Coverage includes:

- Leading Reviews on current and emerging topics relating to neurotherapeutics, subject to rigorous peer review
- Cutting-edge Editorials discussing contentious issues
- Drug Profiles of individual therapies discussing the place of the drug in current treatment practices and written with an independent perspective
- Comprehensive Clinical Trial Reports of recently completed or ongoing clinical studies
- Key Paper Evaluations reviewing significant, recently published articles carefully selected and assessed by specialists in neurotherapeutics.

Expert Review of Neurotherapeutics provides analysis and commentary on the emerging opportunities, new strategies and the performance of new therapeutic and diagnostic modalities. Members of the International Advisory Panel identify the most important and topical review themes and the corresponding experts most appropriate to provide their opinion and perspective. All articles are subject to rigorous peer-review, and the finished articles make an essential contribution to decision-making in the development and delivery of effective therapy in neurology and neuropsychiatry.

Subscription Options

Institutional subscriptions

Expert Review of Neurotherapeutics is available in print, electronic or print and electronic formats, and pricing will depend on your organization type (academic, corporate, hospital, etc). Please contact info@expert-reviews.com for more details.

Global e-access licenses are available on request and attract considerable discounts from standard site license fees. For further details on global access licenses, please contact sales@expert-reviews.com

Consortia pricing

Expert Reviews welcomes discussion with all consortia, and offers flexible packages and discounted prices. If you have specific questions or would like a quote please contact info@expert-reviews.com for more details.

Personal subscriptions

Personal subscriptions are currently available to all Expert Reviews journals. Payment must be made from a personal credit card registered to a home address. Print subscriptions will only be sent to a personal address. Please contact info@expert-reviews.com for our personal order form, or order online at www.future-science-group.com/subscriptions

Subscription Rates	Print & Online			Online only		
	£ GBP	€ Euro	US\$	£ GBP	€ Euro	US\$
Journal (12 issues)						
Academic & Hospital	1225	1620	2145	1105	1470	1940
Corporate, Government & NGO Centers	Please contact info@expert-reviews.com for more details, or contact your local sales representative					

Reprints

Article reprints are available through our reprint service. Please contact Sam Cavana: s.cavana@expert-reviews.com

Ordering Information

Please contact your local sales representative to place an order:

Worldwide

Expert Reviews Ltd
Unitec House, 2 Albert Place, London
N3 1QB, UK
T: +44 (0)20 8371 6080
F: +44 (0)20 8371 6089
E: subscriptions@expert-reviews.com

North America

E: sales.us@expert-reviews.com

Latin America and the Caribbean

dotLib
T: +55 (21) 3431 3430
E: info@dotlib.com

China

Charlesworth China
T: +86 (0)106 779 1601
E: sales@charlesworth.com.cn

Japan

Technomics Inc.
T: +81 (03) 3666 2952
E: sales@technomics.co.jp

Korea

Shinwon Datanet Inc.
T: +822 326 3535
E: info@shinwon.co.kr

Asia (excluding Korea, China & Japan)

Roslinda M. Razi
T: +65 3153 0633
E: r.razi@futuremedicine.com

Middle East

Arabian Advanced Systems
T: +966 1 4770477
E: ammohamed@aas.com.sa



part of the

Argentum Pharm. v. Research Corp. Techs., IPR2016-00204
RCT EX. 2120 - 5/17

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.